Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Immunotherapy has come a long way in head and neck squamous cell carcinoma. Here, Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses the use of these agents as monotherapies vs. their use in combinan moving forwards. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.